<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/archiving/3.0/archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Res</journal-id><journal-id journal-id-type="publisher-id">cvrese</journal-id><journal-id journal-id-type="hwp">cardiovascres</journal-id><journal-title-group><journal-title>Cardiovascular Research</journal-title></journal-title-group><issn pub-type="ppub">0008-6363</issn><issn pub-type="epub">1755-3245</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19088082</article-id><article-id pub-id-type="doi">10.1093/cvr/cvn349</article-id><article-id pub-id-type="publisher-id">cvn349</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cogolludo</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="author-notes" rid="FN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Moreno</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="author-notes" rid="FN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Frazziano</surname><given-names>Giovanna</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Moral-Sanz</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Menendez</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Casta&#x000f1;eda</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Constancio</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Villamor</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Perez-Vizcaino</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Pharmacology, School of Medicine</addr-line>, <institution>University Complutense of Madrid</institution>, <addr-line>28040 Madrid</addr-line>, <country>Spain</country></aff><aff id="af2"><label>2</label><addr-line>Ciber Enfermedades Respiratorias, Ciberes</addr-line>, <country>Spain</country></aff><aff id="af3"><label>3</label><addr-line>Department of Surgery, Intensive Care Unit</addr-line>, <institution>University Hospital of Valladolid</institution>, <addr-line>Valladolid</addr-line>, <country>Spain</country></aff><aff id="af4"><label>4</label><addr-line>Department of Physiology</addr-line>, <institution>University of Valladolid</institution>, <addr-line>Valladolid</addr-line>, <country>Spain</country></aff><aff id="af5"><label>5</label><addr-line>Department of Paediatrics, School for Oncology and Developmental Biology (GROW)</addr-line>, <institution>Maastricht University Medical Centre (MUMC+)</institution>, <addr-line>Maastricht</addr-line>, <country>the Netherlands</country></aff><author-notes><fn id="FN1"><label>&#x02020;</label><p>Both authors contributed equally.</p></fn><corresp id="cor1"><label>*</label>Corresponding author. Tel: <phone>+34 913941477</phone>; fax: <fax>+34 913941464</fax>. <italic>E-mail address</italic>: <email>fperez@med.ucm.es</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>5</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2008</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>82</volume><issue>2</issue><fpage>296</fpage><lpage>302</lpage><history><date date-type="received"><day>1</day><month>9</month><year>2008</year></date><date date-type="rev-recd"><day>25</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Published on behalf of the European Society of Cardiology. All rights reserved. &#x000a9; The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.</copyright-statement><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.</license-p></license></permissions><abstract><sec><title>Aims</title><p>The mechanisms involved in hypoxic pulmonary vasoconstriction (HPV) are not yet fully defined. The aim of the study was to determine the role of protein kinase C &#x003b6; (PKC&#x003b6;) and neutral sphingomyelinase (nSMase) in HPV.</p></sec><sec><title>Methods and results</title><p>Ceramide content was measured by immunocytochemistry and voltage-gated potassium channel (K<sub>V</sub>) currents were recorded by the patch clamp technique in isolated rat pulmonary artery smooth muscle cells (PASMC). Contractile responses were analysed in rat pulmonary arteries mounted in a wire myograph. Pulmonary pressure was recorded in anesthetized open-chest rats. Protein and mRNA expression were measured by western blot and RT&#x02013;PCR, respectively. We found that hypoxia increased ceramide content in PASMC which was abrogated by inhibition of nSMase, but not acid sphingomyelinase (aSMase). The hypoxia-induced vasoconstrictor response in isolated pulmonary arteries and the inhibition of K<sub>V</sub> currents were strongly reduced by inhibition of PKC&#x003b6; or nSMase but not aSMase. The nSMase inhibitor GW4869 prevented HPV <italic>in vivo</italic>. The vasoconstrictor response to hypoxia was mimicked by exogenous addition of bacterial Smase and ceramide. nSMase2 mRNA expression was &#x0223c;10-fold higher in pulmonary compared with mesenteric arteries. In mesenteric arteries, hypoxia failed to increase ceramide but exogenous SMase induced a contractile response.</p></sec><sec><title>Conclusion</title><p>nSMase-derived ceramide production and the activation of PKC&#x003b6; are early and necessary events in the signalling cascade of acute HPV.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Hypoxic pulmonary vasoconstriction</kwd><kwd>Neutral sphingomyelinase</kwd><kwd>Protein kinase C &#x003b6;</kwd><kwd>Pulmonary arteries</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>primary-review-time</meta-name><meta-value><bold>Time for primary review: 30 days</bold></meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><label>1.</label><title>Introduction</title><p>Hypoxic pulmonary vasoconstriction (HPV) is an adaptive physiological mechanism that optimizes blood oxygen saturation by increasing pulmonary vascular resistance in poorly aerated lung regions, thereby diverting pulmonary blood flow to the better ventilated ones.<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>&#x02013;<xref ref-type="bibr" rid="CVN349C7">7</xref></sup> HPV reflects an intrinsic property of the small pulmonary artery (PA) smooth muscle cells (PASMC) in response to alveolar hypoxia. Generalized alveolar hypoxia associated with altitude, atelectasis, chronic obstructive pulmonary disease, or sleep apnea induces HPV which, if sustained, may lead to pulmonary hypertension and right ventricular failure. On the contrary, failure of HPV, as occurs in adult respiratory distress syndrome, pneumonia, sepsis, or liver cirrhosis is often a critical determinant of ventilation&#x02013;perfusion mismatch and, hence, hypoxaemia.<sup><xref ref-type="bibr" rid="CVN349C8">8</xref></sup></p><p>Despite intensive research, the molecular basis of HPV remains one of the most enduring mysteries of cell physiology and several, sometimes contradictory, hypotheses have emerged to explain it.<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>&#x02013;<xref ref-type="bibr" rid="CVN349C7">7</xref>,<xref ref-type="bibr" rid="CVN349C9">9</xref>&#x02013;<xref ref-type="bibr" rid="CVN349C12">12</xref></sup> Nevertheless, there is consensus about the involvement of a putative redox-based O<sub>2</sub> sensor, i.e. mitochondrial electron transport chain<sup><xref ref-type="bibr" rid="CVN349C2">2</xref>,<xref ref-type="bibr" rid="CVN349C4">4</xref>,<xref ref-type="bibr" rid="CVN349C5">5</xref></sup> and/or the membrane NADPH oxidase,<sup><xref ref-type="bibr" rid="CVN349C5">5</xref>,<xref ref-type="bibr" rid="CVN349C7">7</xref></sup> regulating the activity of effector proteins and there is a large body of evidence indicating a role of the reactive oxygen species (ROS) as signalling intermediates. Voltage-gated K<sup>+</sup> (K<sub>V</sub>) channels are known effector proteins which are inhibited by hypoxia, leading to cell membrane depolarization and opening of voltage-dependent L-type Ca<sup>2+</sup> channels.<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>,<xref ref-type="bibr" rid="CVN349C7">7</xref>,<xref ref-type="bibr" rid="CVN349C9">9</xref></sup> Additional effectors include twin pore domain K<sup>+</sup> channels whose inhibition also depolarizes the membrane, store-operated Ca<sup>2+</sup> channels (SOCs) leading to increased capacitative Ca<sup>2+</sup> entry and Rho kinase which is involved in Ca<sup>2+</sup>-sensitization.<sup><xref ref-type="bibr" rid="CVN349C10">10</xref>&#x02013;<xref ref-type="bibr" rid="CVN349C12">12</xref></sup></p><p>We have reported that protein kinase C &#x003b6; (PKC&#x003b6;) is involved in the K<sub>V</sub> channel inhibition and the pulmonary vasoconstriction induced by the thromboxane A<sub>2</sub> mimetic U46619.<sup><xref ref-type="bibr" rid="CVN349C13">13</xref></sup> The role of this kinase, as well as its adaptor protein p62, was recently confirmed using PKC&#x003b6;<sup>&#x02212;/&#x02212;</sup> and p62<sup>&#x02212;/&#x02212;</sup> mice.<sup><xref ref-type="bibr" rid="CVN349C14">14</xref></sup> PKC&#x003b6; is directly activated by ceramide,<sup><xref ref-type="bibr" rid="CVN349C15">15</xref></sup> a sphingolipid-derived second messenger molecule. Ceramide is synthesized from membrane sphingomyelin by sphingomyelin phosphodiesterases (SMPD: SMPD1, SMPD2, SMPD3, and SMPD4), also known as acid or neutral sphingomyelinases (aSMase, nSMase1, nSMase2, and nSMase3, respectively) which are activated by multiple membrane receptors and non-receptor stimuli.<sup><xref ref-type="bibr" rid="CVN349C16">16</xref></sup> SMases-derived ceramide production is an attractive candidate mechanism in HPV because aSMase and nSMase are activated by ROS<sup><xref ref-type="bibr" rid="CVN349C16">16</xref></sup> and SMase and ceramide have been shown to inhibit K<sub>V</sub> channels.<sup><xref ref-type="bibr" rid="CVN349C17">17</xref>,<xref ref-type="bibr" rid="CVN349C18">18</xref></sup></p><p>Herein, we show for the first time that the activation of nSMase and PKC&#x003b6; are necessary events in the signalling of HPV.</p></sec><sec id="s2" sec-type="methods"><label>2.</label><title>Methods</title><p>The investigation conforms with the <italic>Guide for the Care and Use of Laboratory Animals</italic> published by the US National Institutes of Health (NIH Publication No. 85&#x02013;23, revised 1996) and approved by our institutional review board. A detailed description of the experimental methods is available in previous studies.<sup><xref ref-type="bibr" rid="CVN349C13">13</xref>,<xref ref-type="bibr" rid="CVN349C14">14</xref>,<xref ref-type="bibr" rid="CVN349C19">19</xref>,<xref ref-type="bibr" rid="CVN349C20">20</xref></sup> Third generation PA (250&#x02013;450 &#x000b5;m) and mesenteric arteries of similar diameter were isolated from male Wistar rats and smooth muscle cells were enzymatically isolated.</p><sec id="s2a"><label>2.1</label><title>Solutions and hypoxia</title><p>Hepes-buffered solution contained (in mmol/L): NaCl 130, KCl 5, MgCl<sub>2</sub> 1.2, CaCl<sub>2</sub> 1.5, glucose 10, HEPES 10, pH 7.3, and Krebs solution (in mmol/L): NaCl 118, KCl 4,75, NaHCO<sub>3</sub> 25, MgSO<sub>4</sub> 1,2, CaCl<sub>2</sub> 2,0, KH<sub>2</sub>PO<sub>4</sub> 1,2, and glucose 11 bubbled with 21% O<sub>2</sub>, 5%CO<sub>2</sub>. For the <italic>in vitro</italic> experiments, hypoxia was induced by bubbling the Hepes solution with 100% N<sub>2</sub> or the Krebs solution with 95%N<sub>2</sub>&#x02013;5% CO<sub>2</sub> to achieve an oxygen concentration of 3&#x02013;4% (24 &#x000b1; 1 Torr) in the chamber. For the <italic>in vivo</italic> experiments, hypoxia was induced by switching the inspiratory input from room air (&#x0223c;21% O<sub>2</sub>, normoxia) to a 10% O<sub>2</sub>&#x02013;90% N<sub>2</sub> gas.</p></sec><sec id="s2b"><label>2.2</label><title>Ceramide content</title><p>Freshly isolated cells adhered to gelatine-coated coverslips were perfused with Hepes solution for 15 min with or without inhibitors and subsequently with hypoxic solution during 0, 1, 3, or 5 min and rapidly fixed with 4% paraformaldehyde. Cells were stained using an anti-ceramide antibody (15B4) and then with donkey anti-rabbit FITC conjugated antibodies. Immunofluorescence was quantified using ImageJ (ver. 1.32j, NIH).</p></sec><sec id="s2c"><label>2.3</label><title>Contractile responses</title><p>PA rings were mounted in a wire myograph in Krebs solution and stretched to give an equivalent transmural pressure of 30 mmHg.<sup><xref ref-type="bibr" rid="CVN349C21">21</xref></sup> Each vessel was exposed to three hypoxic challenges of 10 min duration each, leaving a 45 min incubation period in normoxia between hypoxic challenges. The third hypoxic response was examined after 45 min incubation with vehicle (control) or different inhibitors and the contractile responses were expressed as a percentage of the second exposure to hypoxia.</p></sec><sec id="s2d"><label>2.4</label><title>Pulmonary arterial pressure</title><p>Pressure was recorded with a pressure transducer in anesthetized (100 mg kg<sup>&#x02212;1</sup> ketamine plus 5 mg kg<sup>&#x02212;1</sup> diazepam) open chest rats via a catheter advanced through the right ventricle and placed into the main PA.</p></sec><sec id="s2e"><label>2.5</label><title>Electrophysiological studies</title><p>Membrane currents were recorded using the whole-cell configuration of the patch clamp technique. Cells were superfused with an external Ca<sup>2+</sup>-free Hepes solution and a Ca<sup>2+</sup>-free pipette (internal) solution containing (mmol/L): KCl 110, MgCl<sub>2</sub> 1.2, Na<sub>2</sub>ATP 5, HEPES 10, EGTA 10, pH adjusted to 7.3 with KOH. Currents were evoked following the application of 200 ms depolarizing pulses from &#x02212;60 mV to test potentials from &#x02212;60 mV to +60 mV in 10 mV increments.</p></sec><sec id="s2f"><label>2.6</label><title>Protein expression</title><p>Protein expression was quantified by western blotting using anti-Kv1.5 (Alomone, Israel), anti-PKC&#x003b6; (Santa Cruz Biotechnology), anti-&#x003b1;-actin (Sigma) antibodies, or an affinity purified rabbit anti-nSMase2 antibody (prepared by Genscript). The synthetic oligopeptide used for immunization was CRRRHPDEAFDHEVS (identical to the 335&#x02013;348 amino acids of rat nSMase2 plus an N-terminal cystein and similar to that used by Tani and Hannun<sup><xref ref-type="bibr" rid="CVN349C22">22</xref></sup>).</p></sec><sec id="s2g"><label>2.7</label><title>Real-time RT&#x02013;PCR</title><p>Total RNA was isolated and purified from arterial homogenates using RNeasy Mini kit (Qiagen). Real-time PCR was performed using a Taqman system (Roche Diagnostics, Mannheim, Germany) in the Unidad de Genomica (Universidad Complutense de Madrid). Specific primers were designed for rat aSMase (right 5&#x02032;- TTTCCCGAGCCCTGTAGA-3&#x02032; and left 5&#x02032;-ATCTGACCCACGCCAATG-3&#x02032;), nSMase1 (right 5&#x02032;-CCCCGTCCACTCTTTCAGTA-3&#x02032; and left 5&#x02032;- GTGCGGGGATCTCAACAT-3), nSMase2 (right 5&#x02032;- TGAAAACATTATTGAGCCTTGC-3&#x02032; and left 5&#x02032;-CTTTGCCACAGCCAATGTC-3&#x02032;), and &#x003b2;-actin (right 5&#x02032;-TCAGGCAGCTCATAGCTCTTC-3&#x02032; and left 5&#x02032;- GCCCTAGACTTCGAGCAAGA-3&#x02032;).</p></sec><sec id="s2h"><label>2.8</label><title>Statistical analysis</title><p>Data are expressed as means &#x000b1; SEM; <italic>n</italic> indicates the number of animals, arteries, or cells tested. For multiple comparisons (e.g. the effects of various inhibitors against a control), statistical analysis was performed using a one-way ANOVA followed by a Bonferroni <italic>post hoc</italic> test, otherwise (e.g. control vs. single treatment) using a two-tailed Student's <italic>t</italic>-test for paired or unpaired observations. Differences were considered statistically significant when <italic>P</italic> &#x0003c; 0.05.</p></sec></sec><sec id="s3"><label>3.</label><title>Results</title><sec id="s3a"><label>3.1</label><title>Effects of hypoxia on ceramide production in isolated pulmonary artery smooth muscle cells</title><p>Exposure to hypoxia induced an increase in ceramide content in freshly isolated PASMC (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F1">1</xref>A</italic>) which was significant after 1 min of perfusion with the hypoxic solution and remained elevated for at least 5 min. We analysed the role of SMases using GW4869,<sup><xref ref-type="bibr" rid="CVN349C23">23</xref></sup> a specific inhibitor of nSMase, and desipramine, specific for aSMase. GW4869, but not desipramine (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F1">1</xref>B</italic>), inhibited hypoxia-induced ceramide production, suggesting that hypoxia-induced ceramide production is derived from nSMase.</p><fig id="CVN349F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Hypoxia induces ceramide production by the activation of nSMase. (<italic>A</italic>) Top panel: time course of the decay in O<sub>2</sub> as measured by a Clark electrode in the chamber. Medium panel: cellular ceramide content determined by immunostaining of PASMC with a monoclonal ceramide-specific antibody 15B4. Bottom panel: representative pictures of immunostained cells after 0, 1, 3, and 5 min of hypoxia. (<italic>B</italic>) Effects of 10 &#x000b5;mol/L GW4869 (GW) and 10 &#x000b5;mol/L desipramine, inhibitors of nSMase and aSMase, respectively, on ceramide production stimulated by 3 min hypoxia. Results are means &#x000b1; SEM (averaged FITC-fluorescence intensity relative to cell surface measured in three to four coverslips with at least 10 cells each), # indicates <italic>P</italic> &#x0003c; 0.05 normoxia vs. hypoxia (unpaired <italic>t</italic>-test), **indicates <italic>P</italic> &#x0003c; 0.01 vs. control (ANOVA followed by a Bonferroni's test).</p></caption><graphic xlink:href="cvn34901"/></fig></sec><sec id="s3b"><label>3.2</label><title>Role of protein kinase C &#x003b6; and nSMase in hypoxia-induced contraction in isolated pulmonary artery</title><p>Hypoxia induced a contractile response in isolated small pulmonary arteries. In the absence of other vasoconstrictor agent, this response was small in magnitude but rapid, sustained, and reproducible (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F2">2</xref>A</italic>) and could also be observed in endothelium-denuded arteries (not shown). The magnitude of this response (0.08 &#x000b1; 0.01 mN, <italic>n</italic> = 10) is approximately 20% of the maximal response induced by the thromboxane A<sub>2</sub> mimetic U46619. This hypoxic contraction was strongly inhibited by the PKC&#x003b6; pseudosubstrate inhibitory peptide (PKC&#x003b6;-PI) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F2">2</xref>B</italic>) suggesting a role for this kinase in HPV. GW4869 and the chemically unrelated nSMase inhibitor manumycin A also inhibited the hypoxic-induced contraction (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F1">1</xref>B</italic>). The effects of desipramine as aSMase inhibitor were not analysed because it is a known Ca<sup>2+</sup> channel antagonist and inhibits agonist- and depolarization-induced contractions in vascular smooth muscle.<sup><xref ref-type="bibr" rid="CVN349C24">24</xref></sup> However, D609,<sup><xref ref-type="bibr" rid="CVN349C25">25</xref></sup> another inhibitor of aSMase, had no effect on hypoxic contraction (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F2">2</xref>B</italic>).</p><fig id="CVN349F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Inhibition of protein kinase C &#x003b6; (PKC&#x003b6;) and nSMase but not aSMase prevents hypoxia-induced vasoconstriction in pulmonary artery (PA) <italic>in vitro</italic>. (<italic>A</italic>) Time course of the contractile response in PA mounted in a wire myograph exposed to hypoxia at time 0 (representative tracing). (<italic>B</italic>) Effects of PKC&#x003b6;-pseudosubstrate inhibitory peptide (10 &#x000b5;mol/L), the nSMase inhibitors GW4869 (10 &#x000b5;mol/L, GW), and manumycin A (5 &#x000b5;mol/L, Manum) or the aSMase inhibitor D609 (100 &#x000b5;mol/L) on the hypoxia-induced PA contraction. Results are means &#x000b1; SEM. **indicates <italic>P</italic> &#x0003c; 0.01 vs. control (ANOVA followed by a Bonferroni's test).</p></caption><graphic xlink:href="cvn34902"/></fig></sec><sec id="s3c"><label>3.3</label><title>Role of nSMase in hypoxic pulmonary vasoconstriction <italic>in vivo</italic></title><p>To analyse the role of nSMase in HPV <italic>in vivo</italic>, we recorded PA pressure via a catheter located in the PA through the right ventricle in open-chest ventilated rats. As expected, hypoxia (10% O<sub>2</sub>) led to a reversible decrease in systemic pressure and an increase in PA pressure, i.e. HPV (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F3">3</xref>A</italic>). Interestingly, in rats treated with GW4869, hypoxia not only failed to increase PA pressure but it even reduced it (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F3">3</xref>B</italic>). On average, hypoxia increased by 7.3 &#x000b1; 1.3 mmHg (<italic>n</italic> = 9) and decreased by 5.3 &#x000b1; 1.1 mmHg (<italic>n</italic> = 11) mean PA pressure in vehicle and GW4869-treated rats, respectively (<italic>P</italic> &#x0003c; 0.05 vehicle vs. GW4869, unpaired Student's <italic>t</italic>-test). The hypoxic-induced pulmonary decrease in PA pressure in GW4869-treated rats was reversible and reproducible (not shown). In other set of experiments in closed chest rats, GW4869 did not modify the hypoxia-induced decrease in systemic pressure (<italic>n</italic> = 5, <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F3">3</xref>B</italic>).</p><fig id="CVN349F3" position="float"><label>Figure&#x000a0;3</label><caption><p>The nSMase inhibitor GW4869 reverses hypoxic pulmonary vasoconstriction <italic>in vivo</italic>. Recordings of systemic (left panel, in closed chest rats via a catheter in the carotid artery) and pulmonary (right panel, in open chest rats via a catheter advanced through the right ventricle into the main pulmonary artery) arterial pressure in anesthetized ventilated rats treated with DMSO (vehicle) (<italic>A</italic>) or 1 mg Kg<sup>&#x02212;1</sup> of GW4869 (<italic>B</italic>) administered intraperitoneally. Rats were exposed to alveolar hypoxia (10% O<sub>2</sub>) as indicated.</p></caption><graphic xlink:href="cvn34903"/></fig></sec><sec id="s3d"><label>3.4</label><title>Effects of exogenous SMase</title><p>As expected, exogenous addition of SMase from <italic>Bacillus cereus</italic>, a homologue of mammalian nSMase, produced a marked increase in ceramide content in isolated PASMC (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F4">4</xref>A</italic>). Moreover, SMase mimicked the effects of hypoxia, i.e. it produced a sustained contractile response (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F4">4</xref>B</italic>) of a similar magnitude (0.10 &#x000b1; 0.04 mN, <italic>n</italic> = 5) to the response induced by hypoxia. However, the time course of this contraction was slower than that induced by hypoxia. This response was also present in endothelium-denuded arteries (not shown). Exogenous addition of C<sub>6</sub>-ceramide also induced a contractile response (0.05 &#x000b1; 0.01 mN, <italic>n</italic> = 32, <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F4">4</xref>C</italic>). This response was inhibited by the PKC&#x003b6;-PI but not by the nSMase inhibitor GW4869. The inhibitory effect of the Rho kinase inhibitor Y27632 and the L-type calcium channel blocker nifedipine on ceramide-induced contraction did not reach statistical significance, but the effects of both drugs combined were highly significant (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F4">4</xref>D</italic>).</p><fig id="CVN349F4" position="float"><label>Figure&#x000a0;4</label><caption><p>Exogenous addition of bacterial SMase reproduces the effects of hypoxia on ceramide content and induces a contractile response in isolated pulmonary artery (PA). (<italic>A</italic>) Effects of SMase (100 mU mL<sup>&#x02212;1</sup> from <italic>Bacillus cereus</italic>) on cellular ceramide content determined by immunostaining of pulmonary artery smooth muscle cells with a monoclonal ceramide-specific antibody 15B4. Cells were exposed to SMase for 15 min. (<italic>B</italic> and <italic>C</italic>) Time course of the contractile response in PA mounted in a wire myograph exposed to SMase (B) and C<sub>6</sub>-ceramide (C) at time 0 (representative tracings). (C) Effects of the nSMase inhibitor GW4869 (10 &#x000b5;mol/L, GW), protein kinase C &#x003b6;-pseudosubstrate inhibitory peptide (10 &#x000b5;mol/L), the L-type Ca<sup>2+</sup> channel inhibitor nifedipine (1 &#x000b5;mol/L, Nifed), the Rho kinase inhibitor Y27632 (10 &#x000b5;mol/L), or the combination of Nifed +Y27632 on the contraction induced by C<sub>6</sub>-ceramide (10 &#x000b5;mol/L) in PA. Results are means &#x000b1; SEM of 6&#x02013;10 experiments (except controls where <italic>n</italic> = 32). * and ** indicates <italic>P</italic> &#x0003c; 0.05 and 0. 0.01, respectively, vs. control (ANOVA followed by a Bonferroni's test).</p></caption><graphic xlink:href="cvn34904"/></fig></sec><sec id="s3e"><label>3.5</label><title>Hypoxic K<sub>V</sub> channel inhibition</title><p>As expected,<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>,<xref ref-type="bibr" rid="CVN349C2">2</xref></sup> we found that hypoxia inhibited K<sub>V</sub> currents (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F5">5</xref></italic>) with a similar time course to the hypoxia-induced ceramide production and contraction. These effects, as shown above for hypoxia-induced vasoconstriction, were prevented by PKC&#x003b6;-PI (included in patch pipette solution) and manumycin A.</p><fig id="CVN349F5" position="float"><label>Figure&#x000a0;5</label><caption><p>Hypoxia-induced inhibition of K<sub>V</sub> currents in pulmonary artery smooth muscle cells (PASMC) is prevented by inhibition of protein kinase C &#x003b6; (PKC&#x003b6;) and nSMase. (<italic>A</italic>) Time course of hypoxia-induced K<sub>V</sub> current inhibition as measured in the whole-cell configuration of the patch-clamp technique in PASMC (average percent change at +30 mV depolarizing pulses and representative current traces for 200 ms depolarization pulses from &#x02212;60 to +60 mV in 10 mV increments from a holding potential of &#x02212;60 mV before and after 5 min of hypoxia), (<italic>B</italic>&#x02013;<italic>D</italic>) Current&#x02013;voltage relationship calculated from experiments as in (A) performed in the absence (B) or in the presence of PKC&#x003b6;-pseudosubstrate inhibitory peptide (0.1 &#x000b5;mol/L in the internal solution) (C) or manumycin (5 &#x000b5;mol/L) (D). Results are means &#x000b1; SEM. *indicates <italic>P</italic> &#x0003c; 0.05 vs. control (paired <italic>t</italic>-test).</p></caption><graphic xlink:href="cvn34905"/></fig></sec><sec id="s3f"><label>3.6</label><title>Pulmonary selectivity</title><p>The mRNAs of aSMase and nSMase1 were similarly expressed in PA and mesenteric arteries as measured by real-time RT&#x02013;PCR (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F6">6</xref>A</italic>). However, the mRNA expression of nSMase2 was much higher in PA when compared with mesenteric arteries. The protein expression of nSMase2, PKC&#x003b6;, and Kv1.5 was also higher in PA as measured by western blot (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F6">6</xref>B</italic>). In addition, hypoxia failed to generate ceramide (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F6">6</xref>C</italic>) in mesenteric arteries. However, exogenous SMase induced a contractile response in isolated mesenteric arteries which was similar to that induced in PA (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F6">6</xref>D</italic>).</p><fig id="CVN349F6" position="float"><label>Figure&#x000a0;6</label><caption><p>Pulmonary selectivity. (<italic>A</italic>) Expression of aSMase, nSMase1, and nSMase2 analysed by RT&#x02013;PCR. Results are normalized to &#x003b2;-actin and expressed as a percent of mean values of PA. (<italic>B</italic>) Protein expression of nSMase2, protein kinase C &#x003b6; (PKC&#x003b6;), and K<sub>V</sub>1.5 analysed by western blot in pulmonary artery (PA) and mesenteric arteries. Blots were re-probed with smooth muscle &#x003b1;-actin as a loading control. Homogenates of Ltk<sup>&#x02212;</sup> cells expressing K<sub>V</sub>1.5 were also loaded in some gels as positive controls. Results are normalized to &#x003b1;-actin and expressed as a percent of mean values of PA. *indicates <italic>P</italic> &#x0003c; 0.05 vs. PA. (<italic>C</italic>) Ceramide production in mesenteric arteries, under normoxia (<italic>n</italic> = 14) and after 3 min hypoxia (<italic>n</italic> = 19), determined by immunostaining with a monoclonal ceramide-specific antibody (15B4). (<italic>D</italic>) Time course of the contractile response in mesenteric arteries mounted in a wire myograph exposed to SMase (100 mU mL<sup>&#x02212;1</sup> from <italic>Bacillus cereus</italic>) at time 0 (representative tracing). Results are means &#x000b1; SEM, <italic>n</italic> is shown in parenthesis.</p></caption><graphic xlink:href="cvn34906"/></fig></sec></sec><sec id="s4"><label>4.</label><title>Discussion</title><p>Herein we show that the activation of nSMase is required for acute HPV (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVN349F7">7</xref></italic>). The specific inhibitors of nSMase but not of aSMase strongly inhibited the constrictor response to hypoxia in small PA. The time course of ceramide generation induced by hypoxia in isolated PASMC and the mimicking effect of exogenous addition of SMase or ceramide are consistent with this view. These events were observed in non-genetically modified systems <italic>in vitro</italic> (rat PA or freshly isolated PASMC) and the role of nSMase was also confirmed <italic>in vivo</italic> by using the specific inhibitor GW4869. The hypoxia-induced increase in ceramide was not observed in mesenteric arteries. In addition, the expression of nSMase2 as well as other signalling proteins PKC&#x003b6; and K<sub>V</sub>1.5 was higher in small PA vs. mesenteric arteries.</p><fig id="CVN349F7" position="float"><label>Figure&#x000a0;7</label><caption><p>Diagram illustrating the proposed signalling cascade involved in hypoxic pulmonary vasoconstriction. The drugs used in the present work as well as their targets are also shown.</p></caption><graphic xlink:href="cvn34907"/></fig><p>HPV <italic>in vivo</italic> is a rapid and sustained response. Because HPV responses are more readily and consistently observed when the small PAs are pre-constricted, the addition of a pre-constrictor agent has been a common practice in many studies analysing HPV <italic>in vitro</italic>. In pre-constricted rat PA, hypoxia produces a tri-phasic response, with an initial vasoconstriction followed by vasodilation and a late slow-developing contraction. However, under the right conditions of stretch, a sustained constrictor response to hypoxia has been reported with no added constrictor agent.<sup><xref ref-type="bibr" rid="CVN349C21">21</xref></sup> In order to avoid a possible influence of a pre-constriction agent on the intracellular signalling mediating HPV, in the present study hypoxic contractions were carried out in the absence of an agonist.</p><p>Several broad inhibitors of PKC isoforms have demonstrated to be effective in inhibiting HPV in isolated perfused lungs.<sup><xref ref-type="bibr" rid="CVN349C26">26</xref></sup> PKC&#x003b6; is activated by hypoxia in alveolar epithelial cells<sup><xref ref-type="bibr" rid="CVN349C27">27</xref></sup> and is a known modulator of K<sub>V</sub> currents in PA.<sup><xref ref-type="bibr" rid="CVN349C13">13</xref>,<xref ref-type="bibr" rid="CVN349C14">14</xref></sup> Our data showing that PKC&#x003b6;-PI prevented the vasoconstriction induced by hypoxia strongly suggest that PKC&#x003b6; is involved in the signalling pathway of HPV.</p><p>PKC&#x003b6; is directly activated by ceramide.<sup><xref ref-type="bibr" rid="CVN349C15">15</xref></sup> Herein, we show that hypoxia induced a rapid increase in ceramide content. The role of nSMase as a source of ceramide was confirmed using the specific inhibitor GW4869,<sup><xref ref-type="bibr" rid="CVN349C23">23</xref></sup> whereas inhibition of aSMase with desipramine was without effect. GW4869 and the chemically unrelated nSMase inhibitor manumycin (but not the aSMase inhibitor D609) inhibited the vasoconstrictor response induced by hypoxia in isolated PA. Moreover, the vasoconstrictor response to hypoxia was mimicked by exogenous addition of bacterial SMase or ceramide. The effects of ceramide were prevented by PKC&#x003b6;-PI. However, GW4869 did not modify ceramide-induced contractions suggesting that the effects of GW4869 are related to the inhibition of nSMase and not to a non-specific effect on smooth muscle contraction. Interestingly, GW4869 completely abolished the hypoxia-induced increase in PA pressure <italic>in vivo</italic>. Moreover, after nSMase inhibition, hypoxia induced a reversible and reproducible decrease in pulmonary arterial pressure, i.e. a characteristic feature of systemic vascular beds. Taken together, these results indicate that nSMase plays a fundamental role in HPV.</p><p>K<sub>V</sub> channels are known targets of hypoxia in PA.<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>,<xref ref-type="bibr" rid="CVN349C2">2</xref></sup> Hypoxia inhibited K<sub>V</sub> currents in PASMC and this effect was prevented by PKC&#x003b6;-PI and manumycin A, implying that hypoxic regulation of K<sub>V</sub> channels is mediated via PKC&#x003b6; and nSMase. However, our data do not exclude that other effector proteins such as Rho kinase, twin pore domain K<sup>+</sup>, or voltage-independent Ca<sup>2+</sup> channels, possibly regulated via nSMAse-derived ceramide, might also be involved in HPV.<sup><xref ref-type="bibr" rid="CVN349C11">11</xref>,<xref ref-type="bibr" rid="CVN349C12">12</xref>,<xref ref-type="bibr" rid="CVN349C28">28</xref></sup> Accordingly, examples of Rho kinase or SOC activation by ceramide have been reported in other cell types.<sup><xref ref-type="bibr" rid="CVN349C29">29</xref>,<xref ref-type="bibr" rid="CVN349C30">30</xref></sup> Herein we also show that the contractile responses induced by ceramide were inhibited by the Rho kinase inhibitor Y27632 and the Ca<sup>2+</sup> channel blocker nifedipine.</p><p>Because vasoconstriction induced by hypoxia is a unique property of the small pulmonary vasculature,<sup><xref ref-type="bibr" rid="CVN349C1">1</xref>&#x02013;<xref ref-type="bibr" rid="CVN349C7">7</xref></sup> the potential mechanisms involved in HPV should be also exclusive to small PA. Thus, we analysed the expression of signalling proteins and the functional differences between PA and mesenteric arteries as prototype systemic arteries. The failure of isolated smooth muscle cells from mesenteric arteries to generate ceramide in response to hypoxia indicates that hypoxic activation of nSMAse is specific of PA. This specificity may be related in part to a higher expression of nSMase2 in small PA. However, it seems also possible that differences in the upstream mechanisms activating nSMase (e.g. the oxygen sensor or the redox response to hypoxia) may account for the pulmonary specificity. The expression of other signalling proteins involved, i.e. PKC&#x003b6; and K<sub>V</sub>1.5 (a specific K<sub>V</sub> channel protein suggested to be involved in HPV<sup><xref ref-type="bibr" rid="CVN349C31">31</xref></sup>), was also higher in PA compared with mesenteric arteries. However, exogenous addition of SMase also induced a contractile response in mesenteric arteries suggesting that pulmonary selectivity is related to differences in the activation of nSMase rather than in the response to SMase.</p><p>Generalized alveolar hypoxia associated with altitude, atelectasis, chronic obstructive pulmonary disease, or sleep apnea leads to HPV and, hence, pulmonary hypertension.<sup><xref ref-type="bibr" rid="CVN349C8">8</xref></sup> The present study identifies nSMase and PKC&#x003b6; as two novel mediators of acute HPV. It is noteworthy that nSMase does not appear to play a role in the control of systemic vascular tone as opposed to its downstream effectors K<sub>V</sub> or L-type Ca<sup>2+</sup> channels, suggesting that their inhibitors may selectively inhibit HPV without inducing systemic hypotension, a common side effect of vasodilators used in pulmonary hypertension. Interestingly, aSMase and PKC&#x003b6; have been also proposed as therapeutic targets in acute lung injury<sup><xref ref-type="bibr" rid="CVN349C25">25</xref></sup> and asthma,<sup><xref ref-type="bibr" rid="CVN349C32">32</xref></sup> respectively.</p></sec><sec id="s5"><title>Funding</title><p>This work was supported by the <funding-source>Spanish Ministerio de Ciencia e Innovaci&#x000f3;n</funding-source> [research grants <award-id>SAF2005-03770</award-id> to F.P.-V., <award-id>SAF2008-03948</award-id> to F.P.-V., <award-id>AGL2004-06685</award-id> to F.P.-V., <award-id>BFU2007-61848</award-id> to C.G., and predoctoral grants: J.M.-S. and G.F. (FPU grants) and C.M. (FPI grant)], by Instituto de Salud Carlos III (CibeRes to F.P.-V. and C.G.) and by Fundaci&#x000f3;n Mutua Madrile&#x000f1;a to A.C. L.M. is funded by a Marie Curie grant. Funding to Pay the Open Access Charges for this article was provided by Ciberes.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors are grateful to Enrique Moreno and Ana Isabel Merino for excellent technical assistance.</p><p><bold>Conflict of interest:</bold> The authors declare no competing financial interests.</p></ack><ref-list><title>References</title><ref id="CVN349C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X-J</given-names></name><name><surname>Goldman</surname><given-names>W</given-names></name><name><surname>Tod</surname><given-names>ML</given-names></name><name><surname>Rubin</surname><given-names>LJ</given-names></name><name><surname>Blaustein</surname><given-names>MP</given-names></name></person-group><article-title>Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes</article-title><source>Am J Physiol</source><year>1993</year><volume>264</volume><fpage>L116</fpage><lpage>L123</lpage><pub-id pub-id-type="pmid">8447425</pub-id></element-citation></ref><ref id="CVN349C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>SL</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Peterson</surname><given-names>D</given-names></name><name><surname>Weir</surname><given-names>EK</given-names></name></person-group><article-title>A redox-based O<sub>2</sub> sensor in rat pulmonary vasculature</article-title><source>Circ Res</source><year>1993</year><volume>73</volume><fpage>1100</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">8222081</pub-id></element-citation></ref><ref id="CVN349C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JQ</given-names></name><name><surname>Sham</surname><given-names>JS</given-names></name><name><surname>Shimoda</surname><given-names>LA</given-names></name><name><surname>Kuppusamy</surname><given-names>P</given-names></name><name><surname>Sylvester</surname><given-names>JT</given-names></name></person-group><article-title>Hypoxic constriction and reactive oxygen species in porcine distal pulmonary arteries</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>285</volume><fpage>L322</fpage><lpage>L333</lpage><pub-id pub-id-type="pmid">12665465</pub-id></element-citation></ref><ref id="CVN349C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waypa</surname><given-names>GB</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Schumacker</surname><given-names>PT</given-names></name></person-group><article-title>Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing</article-title><source>Circ Res</source><year>2001</year><volume>88</volume><fpage>1259</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">11420302</pub-id></element-citation></ref><ref id="CVN349C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Zeller</surname><given-names>S</given-names></name><name><surname>Schafer</surname><given-names>RU</given-names></name><name><surname>Turowski</surname><given-names>C</given-names></name><name><surname>Ay</surname><given-names>M</given-names></name><name><surname>Quanz</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction</article-title><source>Am J Respir Cell Mol Biol</source><year>2006</year><volume>34</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">16357364</pub-id></element-citation></ref><ref id="CVN349C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killilea</surname><given-names>DW</given-names></name><name><surname>Hester</surname><given-names>R</given-names></name><name><surname>Balczon</surname><given-names>R</given-names></name><name><surname>Babal</surname><given-names>P</given-names></name><name><surname>Gillespie</surname><given-names>MN</given-names></name></person-group><article-title>Free radical production in hypoxic pulmonary artery smooth muscle cells</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2000</year><volume>279</volume><fpage>L408</fpage><lpage>L412</lpage><pub-id pub-id-type="pmid">10926565</pub-id></element-citation></ref><ref id="CVN349C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>C</given-names></name><name><surname>Mamary</surname><given-names>AJ</given-names></name><name><surname>Verhoeven</surname><given-names>AJ</given-names></name><name><surname>Marshall</surname><given-names>BE</given-names></name></person-group><article-title>Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction</article-title><source>Am J Respir Cell Mol Biol</source><year>1996</year><volume>15</volume><fpage>633</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">8918370</pub-id></element-citation></ref><ref id="CVN349C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>BE</given-names></name><name><surname>Hanson</surname><given-names>CW</given-names></name><name><surname>Frasch</surname><given-names>F</given-names></name><name><surname>Marshall</surname><given-names>C</given-names></name></person-group><article-title>Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 2. Pathophysiology</article-title><source>Intensive Care Med</source><year>1994</year><volume>20</volume><fpage>379</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">7930036</pub-id></element-citation></ref><ref id="CVN349C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Barneo</surname><given-names>J</given-names></name><name><surname>Lopez-Lopez</surname><given-names>JR</given-names></name><name><surname>Urena</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name></person-group><article-title>Chemotransduction in the carotid body: K<sup>+</sup> current modulated by PO<sub>2</sub> in type I chemoreceptor cells</article-title><source>Science</source><year>1988</year><volume>241</volume><fpage>580</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">2456613</pub-id></element-citation></ref><ref id="CVN349C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurney</surname><given-names>AM</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name></person-group><article-title>The role of twin pore domain and other K<sup>+</sup> channels in hypoxic pulmonary vasoconstriction</article-title><source>Novartis Found Symp</source><year>2006</year><volume>272</volume><fpage>218</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">16686438</pub-id></element-citation></ref><ref id="CVN349C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TP</given-names></name><name><surname>Hague</surname><given-names>D</given-names></name><name><surname>Aaronson</surname><given-names>PI</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name></person-group><article-title>Voltage-independent calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries of the rat</article-title><source>J Physiol</source><year>2000</year><volume>525</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">10856120</pub-id></element-citation></ref><ref id="CVN349C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TP</given-names></name><name><surname>Dipp</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name><name><surname>Aaronson</surname><given-names>PI</given-names></name><name><surname>Evans</surname><given-names>AM</given-names></name></person-group><article-title>Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat</article-title><source>Br J Pharmacol</source><year>2000</year><volume>131</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10960061</pub-id></element-citation></ref><ref id="CVN349C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogolludo</surname><given-names>A</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Bosca</surname><given-names>L</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name><name><surname>Perez-Vizcaino</surname><given-names>F</given-names></name></person-group><article-title>Thromboxane A<sub>2</sub>-induced inhibition of voltage-gated K<sup>+</sup> channels and pulmonary vasoconstriction. Role of protein kinase C&#x003b6;</article-title><source>Circ Res</source><year>2003</year><volume>93</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">12970114</pub-id></element-citation></ref><ref id="CVN349C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Frazziano</surname><given-names>G</given-names></name><name><surname>Cogolludo</surname><given-names>A</given-names></name><name><surname>Cobeno</surname><given-names>L</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name><name><surname>Perez-Vizcaino</surname><given-names>F</given-names></name></person-group><article-title>Role of PKC&#x003b6; and its adaptor protein p62 in K<sub>V</sub> channel modulation in pulmonary arteries</article-title><source>Mol Pharmacol</source><year>2007</year><volume>72</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">17699685</pub-id></element-citation></ref><ref id="CVN349C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourbon</surname><given-names>NA</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Kester</surname><given-names>M</given-names></name></person-group><article-title>Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>35617</fpage><lpage>35623</lpage><pub-id pub-id-type="pmid">10962008</pub-id></element-citation></ref><ref id="CVN349C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulbins</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>PL</given-names></name></person-group><article-title>Physiological and pathophysiological aspects of ceramide</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2006</year><volume>290</volume><fpage>R11</fpage><lpage>R26</lpage><pub-id pub-id-type="pmid">16352856</pub-id></element-citation></ref><ref id="CVN349C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulbins</surname><given-names>E</given-names></name><name><surname>Szabo</surname><given-names>I</given-names></name><name><surname>Baltzer</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name></person-group><article-title>Ceramide-induced inhibition of T lymphocyte voltage-gated potassium channel is mediated by tyrosine kinases</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>7661</fpage><lpage>7666</lpage><pub-id pub-id-type="pmid">9207149</pub-id></element-citation></ref><ref id="CVN349C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ramu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Removal of phospho-head groups of membrane lipids immobilizes voltage sensors of K<sup>+</sup> channels</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>826</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">18273018</pub-id></element-citation></ref><ref id="CVN349C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogolludo</surname><given-names>A</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Lodi</surname><given-names>F</given-names></name><name><surname>Frazziano</surname><given-names>G</given-names></name><name><surname>Cobeno</surname><given-names>L</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Serotonin inhibits voltage-gated K<sup>+</sup> currents in pulmonary artery smooth muscle cells: role of 5-HT<sub>2A</sub> receptors, caveolin-1, and K<sub>V</sub>1.5 channel internalization</article-title><source>Circ Res</source><year>2006</year><volume>98</volume><fpage>931</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">16527989</pub-id></element-citation></ref><ref id="CVN349C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogolludo</surname><given-names>A</given-names></name><name><surname>Frazziano</surname><given-names>G</given-names></name><name><surname>Cobeno</surname><given-names>L</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Lodi</surname><given-names>F</given-names></name><name><surname>Villamor</surname><given-names>E</given-names></name><etal/></person-group><article-title>Role of reactive oxygen species in Kv channel inhibition and vasoconstriction induced by TP receptor activation in rat pulmonary arteries</article-title><source>Ann N Y Acad Sci</source><year>2006</year><volume>1091</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17341601</pub-id></element-citation></ref><ref id="CVN349C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>C</given-names></name><name><surname>Amaki</surname><given-names>Y</given-names></name><name><surname>Marshall</surname><given-names>BE</given-names></name></person-group><article-title>Role of wall tension in hypoxic responses of isolated rat pulmonary arteries</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>L1069</fpage><lpage>L1077</lpage><pub-id pub-id-type="pmid">9843843</pub-id></element-citation></ref><ref id="CVN349C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>M</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name></person-group><article-title>Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>10047</fpage><lpage>10056</lpage><pub-id pub-id-type="pmid">17272284</pub-id></element-citation></ref><ref id="CVN349C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luberto</surname><given-names>C</given-names></name><name><surname>Hassler</surname><given-names>DF</given-names></name><name><surname>Signorelli</surname><given-names>P</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Sawai</surname><given-names>H</given-names></name><name><surname>Boros</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>41128</fpage><lpage>41139</lpage><pub-id pub-id-type="pmid">12154098</pub-id></element-citation></ref><ref id="CVN349C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez del Pozo</surname><given-names>B</given-names></name><name><surname>Perez-Vizcaino</surname><given-names>F</given-names></name><name><surname>Fernandez</surname><given-names>C</given-names></name><name><surname>Zaragoza</surname><given-names>F</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name></person-group><article-title>Effects of several class I antiarrhythmic drugs on isolated rat aortic vascular smooth muscle</article-title><source>Gen Pharmacol</source><year>1997</year><volume>29</volume><fpage>539</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">9352299</pub-id></element-citation></ref><ref id="CVN349C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goggel</surname><given-names>R</given-names></name><name><surname>Winoto-Morbach</surname><given-names>S</given-names></name><name><surname>Vielhaber</surname><given-names>G</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Lindner</surname><given-names>K</given-names></name><name><surname>Brade</surname><given-names>L</given-names></name><etal/></person-group><article-title>PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">14704790</pub-id></element-citation></ref><ref id="CVN349C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barman</surname><given-names>SA</given-names></name></person-group><article-title>Effect of protein kinase C inhibition on hypoxic pulmonary vasoconstriction</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2001</year><volume>280</volume><fpage>L888</fpage><lpage>L895</lpage><pub-id pub-id-type="pmid">11290512</pub-id></element-citation></ref><ref id="CVN349C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dada</surname><given-names>LA</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Ridge</surname><given-names>KM</given-names></name><name><surname>Pedemonte</surname><given-names>C</given-names></name><name><surname>Bertorello</surname><given-names>AM</given-names></name><name><surname>Sznajder</surname><given-names>JI</given-names></name></person-group><article-title>Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1057</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">12671055</pub-id></element-citation></ref><ref id="CVN349C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Dietrich</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>B</given-names></name><name><surname>Kalwa</surname><given-names>H</given-names></name><name><surname>Ay</surname><given-names>M</given-names></name><name><surname>Dumitrascu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>19093</fpage><lpage>19098</lpage><pub-id pub-id-type="pmid">17142322</pub-id></element-citation></ref><ref id="CVN349C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>VR</given-names></name><name><surname>Schneider</surname><given-names>MD</given-names></name><name><surname>Entman</surname><given-names>ML</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><etal/></person-group><article-title>Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>14495</fpage><lpage>14500</lpage><pub-id pub-id-type="pmid">16983089</pub-id></element-citation></ref><ref id="CVN349C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colina</surname><given-names>C</given-names></name><name><surname>Flores</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>H</given-names></name><name><surname>Acosta</surname><given-names>A</given-names></name><name><surname>Castillo</surname><given-names>C</given-names></name><name><surname>Garrido Mdel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ceramide increase cytoplasmic Ca<sup>2+</sup> concentration in Jurkat T cells by liberation of calcium from intracellular stores and activation of a store-operated calcium channel</article-title><source>Arch Biochem Biophys</source><year>2005</year><volume>436</volume><fpage>333</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">15797246</pub-id></element-citation></ref><ref id="CVN349C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platoshyn</surname><given-names>O</given-names></name><name><surname>Brevnova</surname><given-names>EE</given-names></name><name><surname>Burg</surname><given-names>ED</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Remillard</surname><given-names>CV</given-names></name><name><surname>Yuan</surname><given-names>JX</given-names></name></person-group><article-title>Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells</article-title><source>Am J Physiol Cell Physiol</source><year>2006</year><volume>290</volume><fpage>C907</fpage><lpage>C916</lpage><pub-id pub-id-type="pmid">16236819</pub-id></element-citation></ref><ref id="CVN349C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Villares</surname><given-names>R</given-names></name><name><surname>Rodriguez-Mascarenhas</surname><given-names>S</given-names></name><name><surname>Zaballos</surname><given-names>A</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Kovac</surname><given-names>J</given-names></name><etal/></person-group><article-title>Control of T helper 2 cell function and allergic airway inflammation by PKCzeta</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>9866</fpage><lpage>9871</lpage><pub-id pub-id-type="pmid">15987782</pub-id></element-citation></ref></ref-list></back></article>